Company Overview
More
Tengsheng Boyao Biotechnology Co., Ltd. is a biotechnology company headquartered in China and the United States, mainly engaged in infectious disease therapy research and development business. The company's products are used in infectious diseases (such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multidrug-resistant (MDR) or extensively drug-resistant (XDR) Gram-negative bacteria infections) and other diseases with significant public health burdens, such as central nervous system (CNS) diseases. The company also develops treatments for COVID-19 and others.
CEO： Zhi HONG
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
02137 BRII-B
8.200+0.100+1.23%
YOY
Do not show
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(FY)2019/12/31
Assets
Current assets
Advance deposits and other receivables
72.57%
58.88M
--
43.99M
618.47%
34.12M
--
4.75M
Cash and equivalents
175.86%
2.86B
--
1.44B
17.56%
1.03B
--
880.36M
Short-term deposit
2398.24%
499.65M
--
--
--
20M
--
--
Secured deposit
-91.51%
319K
--
323K
976.5%
3.76M
--
349K
Total current assets
212.39%
3.41B
--
1.49B
23.42%
1.09B
--
885.46M
Non-current assets
Property, plant and equipment
-23.83%
12.57M
--
15.86M
-22.63%
16.51M
--
21.33M
Advance payment
15.41%
2.79M
--
3.03M
4.19%
2.41M
--
2.32M
Financial assets at fair value-non-current assets
56.29%
117.79M
--
74.62M
3.54%
75.37M
--
72.79M
Intangible assets
-22.22%
9.51M
--
10.86M
--
12.22M
--
--
Special items of non-current assets
-19.67%
55.1M
--
75.89M
19.23%
68.6M
--
57.53M
Total non-current assets
12.94%
197.76M
--
180.27M
13.73%
175.1M
--
153.97M
Total assets
184.85%
3.61B
--
1.67B
21.99%
1.27B
--
1.04B
Liabilities
Current liabilities
Other payables and accrued expenses
-56%
218.86M
--
117.19M
2709.16%
497.39M
--
17.71M
Financial lease liabilities-current liabilities
11.82%
8.97M
--
9.25M
-0.61%
8.02M
--
8.07M
Deferred income-current liabilities
-24.26%
52.88M
--
26.8M
93.38%
69.82M
--
36.11M
Total current liabilities
-51.2%
280.71M
--
153.24M
829.54%
575.24M
--
61.88M
Net current assets
505.33%
3.13B
--
1.34B
-37.15%
517.61M
--
823.57M
Total assets less current liabilities
380.86%
3.33B
--
1.52B
-29.14%
692.71M
--
977.54M
Non-current liabilities
Financial lease liabilities-non-current liabilities
-37.72%
12.65M
--
18.17M
-24.91%
20.31M
--
27.04M
Deferred income-non-current liabilities
-41.38%
7.08M
--
9.58M
-56.72%
12.08M
--
27.92M
Special items of non-current liabilities
--
--
--
6.13B
56.51%
2.4B
--
1.54B
Total non-current liabilities
-99.19%
19.73M
--
6.15B
53.14%
2.44B
--
1.59B
Total liabilities
-90.02%
300.44M
--
6.31B
82.22%
3.01B
--
1.65B
Total assets less total liabilities
290.01%
3.31B
--
-4.64B
-184.4%
-1.74B
--
-612.76M
Total equity and non-current liabilities
380.86%
3.33B
--
1.52B
-29.14%
692.71M
--
977.54M
Equity
Share capital
228.57%
23K
--
7K
0%
7K
--
7K
Share premium
292.31%
3.34B
--
-4.63B
-183.68%
-1.74B
--
-612.77M
Shareholders' Equity
292.31%
3.34B
--
-4.63B
-183.68%
-1.74B
--
-612.76M
Non-controlling interest
-617.15%
-31.65M
--
-4.82M
--
-4.41M
--
--
Total equity
290.01%
3.31B
--
-4.64B
-184.4%
-1.74B
--
-612.76M
Total equity and total liabilities
184.85%
3.61B
--
1.67B
21.99%
1.27B
--
1.04B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified OpinionUnqualified Opinion
Auditor
Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang AccountantsDeloitte Guan Huang Chen Fang Accountants
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%